A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00605163
Verified March 2008 by The Parkinson Study Group. Recruitment status was: Enrolling by invitation
: January 30, 2008
Last Update Posted
: March 28, 2008
The Parkinson Study Group
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Parkinson disease patients who participated in the PRECEPT clinical trial.
Participation in the PRECEPT study
Willing and able to give informed consent
Patients will be excluded from participating in the the study if either of the criteria stated above is not met